Blue Earth touts fluciclovine F-18 research at ASCO GU

AuntMinnie.com staff writers

Feb 7, 2021

2021 01 16 00 14 5464 Prostate Cancer 400

Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting research on its Axumin (fluciclovine F-18) PET radiopharmaceutical at the upcoming American Society for Clinical Oncology Genitourinary (ASCO GU) virtual meeting.

Research will cover the diagnostic utility of fluciclovine F-18 PET in biochemically recurrent prostate cancer based on prior primary treatment modality for localized disease and the impact of those findings on treatment, using fluciclovine F-18 PET/CT for prostate cancer, and fluciclovine F-18 PET in metastatic castration-resistant prostate cancer treated with abiraterone acetate.

PET/MRI reveals sex differences in patients with autism

April 18, 2024

PET tracer for gliomas under expedited review

April 17, 2024

Driving the future of PET/CT.

Driving the future of PET/CT.

April 17, 2024

Predictions and Grad-CAMs of ViT-based models on sample PET/CT, PET, and CT test images from the “positive” class. ViT was fine-tuned using training data for each modality. The bounding boxes depicted in the figure indicate malignant lesions. The top row of the Grad-CAMs shows important areas for “positive” predictions, and the bottom row shows areas for “negative” predictions. Image courtesy of Scientific Reports.

Vision transformer AI model boosts PET/CT imaging of cancer

April 12, 2024

PET/MRI reveals sex differences in patients with autism

PET/MRI shows that young women with autism spectrum disorder have increased brain metabolism associated with translocator protein.

April 18, 2024

PET tracer for gliomas under expedited review

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to Telix Pharmaceuticals’ PET radiotracer F-18 floretyrosine (Pixclara) for imaging progressive or recurring gliomas.

April 17, 2024

FAPI-PET shows promise in patients with lung cancer

FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans.

April 15, 2024

F-18 FDG and Ga-68 FAPI-46 images of a 51-year-old woman with adenocarcinoma with lepidic growth pattern in right upper lobe. (A) Maximum-intensity-projection PET images. The lesion had F-18 FDG uptake below blood pool level but was strongly Ga-68 FAPI-46-positive. CT-guided biopsy led to pathologic diagnosis of adenocarcinoma, and the patient was treated by stereotactic body radiation therapy because of functional inoperability. Image courtesy of the Journal of Nuclear Medicine.

Vision transformer AI model boosts PET/CT imaging of cancer

A vision transformer AI model outperformed convolutional neural networks when classifying tumors on PET/CT images as benign or malignant.

April 12, 2024

Predictions and Grad-CAMs of ViT-based models on sample PET/CT, PET, and CT test images from the “positive” class. ViT was fine-tuned using training data for each modality. The bounding boxes depicted in the figure indicate malignant lesions. The top row of the Grad-CAMs shows important areas for “positive” predictions, and the bottom row shows areas for “negative” predictions. Image courtesy of Scientific Reports.

Can AI improve sustainability in nuclear medicine?

Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.

April 9, 2024

ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.

PET/MRI detects brain injury in pediatric cancer survivors

PET/MRI could be a tool for diagnosing brain injury due to high-dose methotrexate treatment in young cancer survivors.

April 8, 2024

A visual abstract of the study. Image courtesy of the Journal of Nuclear Medicine.

Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio

By AuntMinnie.com staff writers

Life Molecular Imaging and Sofie Biosciences have begun offering the Neuraceq PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio.

April 5, 2024

Brain Puzzle Dementia Social

CDL Nuclear Technologies launches mobile cardiac PET/CT trailer

By AuntMinnie.com staff writers

The company said the mobile trailer complements its other services, which include PET/CT buildouts and on-demand daily use rubidium-82 radioisotope services.

April 5, 2024

The rise of theranostics: Part 2 -- Moving into communities

In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.

April 4, 2024

Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)

SPECT/CT algorithm predicts heart failure hospitalizations

AI can effectively predict hospitalization for acute heart failure exacerbation in patients undergoing SPECT/CT myocardial perfusion imaging.

April 3, 2024

A visual abstract of the study by the authors. Image courtesy of the Journal of Nuclear Medicine.

SNMMI to tackle Capitol Hill

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.

April 3, 2024

PET/MRI may improve diagnosis of Cushing disease

PET/MRI could become the diagnostic method of choice over MRI alone for identifying small pituitary tumors associated with Cushing disease.

March 29, 2024

T1-weighted postgadolinium MR images (A and C) and F-18 FET-PET/MR images (B and D) centered at pituitary before (A and B) and after (C and D) transsphenoidal surgery. This patient with Cushing disease showed clear focal uptake (B) but no clear lesion on previously obtained and accompanying MRI (A). Postoperative tissue analysis did confirm resection of small pituitary adenoma/PitNET, and postoperative F-18 FET-PET showed no residual uptake (D). Image courtesy of the Journal of Nuclear Medicine.

Page 1 of 592